Raj Suryanarayanan serves as Professor, William & Mildred Peters Endowed Chair, and Department Head of the Department of Pharmaceutics at the University of Minnesota. His research program focuses on the material science of pharmaceutical solids, with particular emphasis on physical characterization of polymorphic forms, crystallinity, and water interactions in drug products. Education: PhD in Pharmaceutics, University of British Columbia MPharm in Pharmaceutics, Indian Institute of Technology, Varanasi BPharm in Pharmaceutics, Indian Institute of Technology, Varanasi Research Focus: Dr. Suryanarayanan's laboratory investigates phase transitions during pharmaceutical processing using advanced techniques including X-ray powder diffractometry, thermoanalytical methods, spectroscopy, and microscopy. Key research areas include in-situ monitoring of freeze-drying cycles for protein pharmaceuticals, quantification of rapid reaction phases (40 msec resolution), microdiffractometry for tablet surface mapping, and development of novel excipients for freeze-dried formulations. His work bridges fundamental material science with practical formulation challenges to ensure reproducible solid dosage form performance. Publication Trends: Recent publications (2023-2025) reveal a dominant focus on monoclonal antibody stability in freeze-dried systems, excipient functionality (particularly mannitol and sucrose), and advanced characterization of frozen solutions. The research demonstrates sophisticated integration of solid-state NMR, X-ray diffraction, and thermal analysis to resolve phase transitions and molecular mobility issues. A clear trajectory emerges toward solving industry-relevant problems in biologics formulation, with increasing emphasis on predictive stability models and continuous manufacturing implications. Scientific Recognition: Honored with a dedicated issue of the Journal of Pharmaceutical Sciences (January 2023) Research Leadership: As Department Head and Endowed Chair, Dr. Suryanarayanan directs the Sury Research Group which has secured significant funding including GOALI/Collaborative Research awards. His laboratory maintains specialized instrumentation for real-time monitoring of pharmaceutical processing, particularly custom-built systems for freeze-drying cycle optimization. The group maintains strong industry collaborations focused on solving critical formulation challenges in protein therapeutics and amorphous solid dispersions. Facilities: The Sury Lab operates advanced characterization equipment including synchrotron X-ray diffractometers, solid-state NMR, and custom microdiffractometry systems specifically engineered for mapping tablet heterogeneity and monitoring rapid phase transitions during processing.
